New Crystalline form-M, form-S of Pirtobrutinib are Bruton's tyrosine kinase inhibitor for treating adult patients with relapsed or refractory mantle cell lymphoma, is characterized by powder X-Ray diffraction pattern having specific peaks
	BALRAJU K; REDDY S R; RAJAN S T
	2023-09-08
专利权人	MSN LAB PRIVATE LTD R & D CENT (MSNM-Non-standard)
申请日期	2023-09-08
专利号	IN202341060529-A
成果简介	NOVELTY - Crystalline form-M, form-S of Pirtobrutinib are new, where the form-M is characterized by powder X-Ray diffraction (PXRD) pattern having peaks at 5.0°, 10.0°, 12.1°, 5 15.1°, 15.7°, 16.2°, 16.6°, 17.2°, 19.3°, 19.9°, 20.8°, 21.4°, 23.4°, 24.3°, 24.9°, 29.1° and 31.7° 2θ± 0.2° 2θ; and/or PXRD pattern as depicted in Figure 1; and the form-S is characterized by Powder X-Ray diffraction pattern having peaks at 10.1°, 11.3°, 14.3°, 15.2°, 16.0°, 16.6°, 17.6°, 18.3°, 20.2°, 21.0°, 21.9°, 25.0°, 28.9° and 32.5° 2θ± 0.2° 2θ, and/or as depicted in Figure 2. USE - Crystalline form-M, form-S of Pirtobrutinib for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL). No biological data given. ADVANTAGE - None given. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for: a process for the preparation of crystalline form-M, form-S of Pirtobrutinib of formula (I); a process for preparing amorphous form of Pirtobrutinib (I), comprising: (a) dissolving Pirtobrutinib in dichloromethane; (b) isolating amorphous form of Pirtobrutinib (I).
IPC 分类号	A61K-031/415 ; C07C-055/14 ; C07C-061/06 ; C07D-231/38
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/20460
专题	中国科学院新疆生态与地理研究所
作者单位	MSN LAB PRIVATE LTD R & D CENT (MSNM-Non-standard)
推荐引用方式 GB/T 7714	BALRAJU K,REDDY S R,RAJAN S T. New Crystalline form-M, form-S of Pirtobrutinib are Bruton's tyrosine kinase inhibitor for treating adult patients with relapsed or refractory mantle cell lymphoma, is characterized by powder X-Ray diffraction pattern having specific peaks. IN202341060529-A[P]. 2023.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。